DOCSLIB.ORG

Hemopericardium and Acute Cardiac Tamponade

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hemopericardium and Acute Cardiac Tamponade IMAGES IN ANESTHESIOLOGY Brian P. Kavanagh, M.B., F.R.C.P.C., Editor Hemopericardium and Acute Cardiac Tamponade Sandeep Khanna, M.D., Kamal Maheshwari, M.D., M.P.H. EMOPERICARDIUM leading to acute cardiac tampon- H ade is a true emergency. The accompanying transesophageal echocardiography images exhibit such an occurrence. A significant effusion is layering both the ventricles (top panel). A large clot in the pericardial space is compressing the free wall of the right ventricle (bottom panel). Being thin-walled, the right atrium is most prone to compression (see video, Supplemental Digital Content, http:// links.lww.com/ALN/B571, which demonstrates clot impinging on right atrium). Common causes include malignancy, aortic dissec- tion, myocardial wall rupture, cardiac surgery, and chest trauma.1–3 Rapid bleeding into the pericardial sac overwhelms its capac- ity to stretch. Consequently, intrapericardial pressures rise acutely, impeding diastolic filling and systolic ejection. Cardiac output decreases precipitously resulting in shock. Tamponade is essentially a clinical diagnosis. Intractable hypotension, tachycardia, jugular venous distension, and pulsus paradoxus suggest the diagnosis. Echocardiography is corroborative. Specific signs include diastolic right ventricular and left atrial collapse.1–3 Differentials include right ventricular myocardial infarction and pulmonary embolism. Hemodynamic instability necessitates pericardial decompres- sion via surgical drainage. Aortic dissection and myocardial wall rupture should be excluded, because decompression may lead to catastrophic exsanguination in these conditions.1,2 Anesthetic considerations include liberal volume loading and maintenance of high normal systemic vascular resistance. As endogenous cat- echolamine response is maximal, the role of inotropes is limited. Invasive arterial monitoring and large-bore IV access are desirable. Prior to induction, it is prudent to have the surgical team prepare and drape the patient, in readiness for incision. Bradycardia, excessive peak airway pressures, and high positive end-expiratory pressure are scrupulously avoided.3 Competing Interests The authors declare no competing interests. Correspondence Address correspondence to Dr. Khanna: [email protected] References 1. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Eur Heart J 2015; 36:2921–64 2. Spodick DH: Acute cardiac tamponade. N Engl J Med 2003; 349:684–90 3. O’Connor CJ, Tuman KJ: The intraoperative management of patients with pericardial tamponade. Anesthesiol Clin 2010; 28:87–96 Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal’s Web site (www. anesthesiology.org). Charles D. Collard, M.D., served as Handling Editor for this article. From the Department of General Anesthesia (S.K., K.M.) and the Department of OUTCOMES RESEARCH (K.M.), Anesthesiology Institute, Cleveland Clinic Foundation, Cleveland, Ohio. Copyright © 2018, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. All Rights Reserved. Anesthesiology 2018; 128:1006 Anesthesiology, V 128 • No 5 1006 May 2018 Copyright © 2017, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited. Downloaded From: http://anesthesiology.pubs.asahq.org/ by Alparslan<zdoi;10.1097/ALN.0000000000001999> Turan on 01/08/2019.
Load more

Recommended publications
  • Constrictive Pericarditis Causing Ventricular Tachycardia.Pdf
    EP CASE REPORT ....................................................................................................................................................... A visually striking calcific band causing monomorphic ventricular tachycardia as a first presentation of constrictive pericarditis Kian Sabzevari 1*, Eva Sammut2, and Palash Barman1 1Bristol Heart Institute, UH Bristol NHS Trust UK, UK; and 2Bristol Heart Institute, UH Bristol NHS Trust UK & University of Bristol, UK * Corresponding author. Tel: 447794900287; fax: 441173425926. E-mail address: [email protected] Introduction Constrictive pericarditis (CP) is a rare condition caused by thickening and stiffening of the pericar- dium manifesting in dia- stolic dysfunction and enhanced interventricu- lar dependence. In the developed world, most cases are idiopathic or are associated with pre- vious cardiac surgery or irradiation. Tuberculosis remains a leading cause in developing areas.1 Most commonly, CP presents with symptoms of heart failure and chest discomfort. Atrial arrhythmias have been described as a rare pre- sentation, but arrhyth- mias of ventricular origin have not been reported. Figure 1 (A) The 12 lead electrocardiogram during sustained ventricular tachycardia is shown; (B and C) Case report Different projections of three-dimensional reconstructions of cardiac computed tomography demonstrating a A 49-year-old man with a striking band of calcification around the annulus; (D) Carto 3DVR mapping—the left hand panel (i) demonstrates a background of diabetes, sinus beat with late potentials at the point of ablation in the coronary sinus, the right hand panel (iii) shows the hypertension, and hyper- pacemap with a 89% match to the clinical tachycardia [matching the morphology seen on 12 lead ECG (A)], and cholesterolaemia and a the middle panel (ii) displays the three-dimensional voltage map.
    [Show full text]
  • J Wave Syndromes
    Review Article http://dx.doi.org/10.4070/kcj.2016.46.5.601 Print ISSN 1738-5520 • On-line ISSN 1738-5555 Korean Circulation Journal J Wave Syndromes: History and Current Controversies Tong Liu, MD1, Jifeng Zheng, MD2, and Gan-Xin Yan, MD3,4 1Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin, 2Department of cardiology, The Second Hospital of Jiaxing, Jiaxing, China, 3Lankenau Institute for Medical Research and Lankenau Medical Center, Wynnewood, Pennsylvania, USA, 4The First Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, China The concept of J wave syndromes was first proposed in 2004 by Yan et al for a spectrum of electrocardiographic (ECG) manifestations of prominent J waves that are associated with a potential to predispose affected individuals to ventricular fibrillation (VF). Although the concept of J wave syndromes is widely used and accepted, there has been tremendous debate over the definition of J wave, its ionic and cellular basis and arrhythmogenic mechanism. In this review article, we attempted to discuss the history from which the concept of J wave syndromes (JWS) is evolved and current controversies in JWS. (Korean Circ J 2016;46(5):601-609) KEY WORDS: Brugada syndrome; Sudden cardiac death; Ventricular fibrillation. Introduction History of J wave and J wave syndromes The concept of J wave syndromes was first proposed in 2004 The J wave is a positive deflection seen at the end of the QRS by Yan et al.1) for a spectrum of electrocardiographic (ECG) complex; it may stand as a distinct “delta” wave following the QRS, manifestations of prominent J waves that are associated with a or be partially buried inside the QRS as QRS notching or slurring.
    [Show full text]
  • The Syndrome of Alternating Bradycardia and Tachycardia by D
    Br Heart J: first published as 10.1136/hrt.16.2.208 on 1 April 1954. Downloaded from THE SYNDROME OF ALTERNATING BRADYCARDIA AND TACHYCARDIA BY D. S. SHORT From the National Heart Hospita. Received September 15, 1953 Among the large number of patients suffering from syncopal attacks who attended the National Heart Hospital during a four-year period, there were four in whom examination revealed sinus bradycardia alternating with prolonged phases of auricular tachycardia. These patients presented a difficult problem in treatment. Each required at least one admission to hospital and in one case the symptoms were so intractable as to necessitate six admissions in five years. Two patients had mitral valve disease, one of them with left bundle branch block. One had aortic valve sclerosis while the fourth had no evidence of heart disease. THE HEART RATE The sinus rate usually lay between 30 and 50 a minute, a rate as slow as 22 a minute being observed in one patient (Table I). Sinus arrhythmia was noted in all four patients, wandering of TABLE I http://heart.bmj.com/ RATE IN SINus RHYTHM AND IN AURICULAR TACHYCARDIA Rate in Case Age Sex Associated Rate in auricular tachycardia heart disease sinus rhythm Auricular Venliicular 1 65 M Aortic valve sclerosis 28-48 220-250 60-120 2 47 F Mitral valve disease 35-75 180-130 90-180 on September 26, 2021 by guest. Protected copyright. 3 38 F Mitral valve disease 22-43 260 50-65 4 41 F None 35-45 270 110 the pacemaker in three, and periods of sinus standstill in two (Fig.
    [Show full text]
  • Unstable Angina with Tachycardia: Clinical and Therapeutic Implications
    Unstable angina with tachycardia: Clinical and therapeutic implications We prospectively evaluated 19 patients with prolonged chest pain not evolving to myocardiai infarction and accompanied with reversible ST-T changes and tachycardia (heart rate >lOO beats/min) in order to correlate heart rate reduction with ischemic electrocardiographic (ECG) changes. Fourteen patients (74%) received previous long-term combined treatment with nifedipine and nitrates. Continuous ECG monitoring was carried out until heart rate reduction and at least one of the following occurred: (1) relief of pain or (2) resolution of ischemic ECG changes. The study protocol consisted of carotid massage in three patients (IS%), intravenous propranolol in seven patients (37%), slow intravenous amiodarone infusion in two patients (lo%), and intravenous verapamil in four patients (21%) with atrial fibrillation. In three patients (16%) we observed a spontaneous heart rate reduction on admission. Patients responded with heart rate reduction from a mean of 126 + 10.4 beats/min to 64 k 7.5 beats/min (p < 0.005) and an ST segment shift of 4.3 k 2.13 mm to 0.89 k 0.74 mm (p < 0.005) within a mean interval of 13.2 + 12.7 minutes. Fifteen (79%) had complete response and the other four (21%) had partial relief of pain. A significant direct correlation was observed for heart rate reduction and ST segment deviation (depression or elevation) (f = 0.7527 and 0.8739, respectively). These patients represent a unique subgroup of unstable angina, in which the mechanism responsible for ischemia is excessive increase in heart rate. Conventional vasodilator therapy may be deleterious, and heart rate reduction Is mandatory.
    [Show full text]
  • Tachycardia (Fast Heart Rate)
    Tachycardia (fast heart rate) Working together to improve the diagnosis, treatment and quality of life for all those aff ected by arrhythmias www.heartrhythmalliance.org Registered Charity No. 1107496 Glossary Atrium Top chambers of the heart that receive Contents blood from the body and from the lungs. The right atrium is where the heart’s natural pacemaker (sino The normal electrical atrial node) can be found system of the heart Arrhythmia An abnormal heart rhythm What are arrhythmias? Bradycardia A slow heart rate, normally less than 60 beats per minute How do I know what arrhythmia I have? Cardiac Arrest the abrupt loss of heart function, breathing and consciousness Types of arrhythmia Cardioversion a procedure used to return an abnormal What treatments are heartbeat to a normal rhythm available to me? Defi brillation a treatment for life-threatening cardiac arrhythmias. A defibrillator delivers a dose of electric current to the heart Important information This booklet is intended for use by people who wish to understand more about Tachycardia. The information within this booklet comes from research and previous patients’ experiences. The booklet off ers an explanation of Tachycardia and how it is treated. This booklet should be used in addition to the information given to you by doctors, nurses and physiologists. If you have any questions about any of the information given in this booklet, please ask your nurse, doctor or cardiac physiologist. 2 Heart attack A medical emergency in which the blood supply to the heart is blocked, causing serious damage or even death of heart muscle Tachycardia Fast heart rate, more than 100 beats per minute Ventricles The two lower chambers of the heart.
    [Show full text]
  • Pericardial Disease and Other Acquired Heart Diseases
    Royal Brompton & Harefield NHS Foundation Trust Pericardial disease and other acquired heart diseases Sylvia Krupickova Exam oriented Echocardiography course, 4th November 2016 Normal Pericardium: 2 layers – fibrous - serous – visceral and parietal layer 2 pericardial sinuses – (not continuous with one another): • Transverse sinus – between in front aorta and pulmonary artery and posterior vena cava superior • Oblique sinus - posterior to the heart, with the vena cava inferior on the right side and left pulmonary veins on the left side Normal pericardium is not seen usually on normal echocardiogram, neither the pericardial fluid Acute Pericarditis: • How big is the effusion? (always measure in diastole) • Where is it? (appears first behind the LV) • Is it causing haemodynamic compromise? Small effusion – <10mm, black space posterior to the heart in parasternal short and long axis views, seen only in systole Moderate – 10-20 mm, more than 25 ml in adult, echo free space is all around the heart throughout the cardiac cycle Large – >20 mm, swinging motion of the heart in the pericardial cavity Pericardiocentesis Constrictive pericarditis Constriction of LV filling by pericardium Restriction versus Constriction: Restrictive cardiomyopathy Impaired relaxation of LV Constriction versus Restriction Both have affected left ventricular filling Constriction E´ velocity is normal as there is no impediment to relaxation of the left ventricle. Restriction E´ velocity is low (less than 5 cm/s) due to impaired filling of the ventricle (impaired relaxation)
    [Show full text]
  • Common Types of Supraventricular Tachycardia: Diagnosis and Management RANDALL A
    Common Types of Supraventricular Tachycardia: Diagnosis and Management RANDALL A. COLUCCI, DO, MPH, Ohio University College of Osteopathic Medicine, Athens, Ohio MITCHELL J. SILVER, DO, McConnell Heart Hospital, Columbus, Ohio JAY SHUBROOK, DO, Ohio University College of Osteopathic Medicine, Athens, Ohio The most common types of supraventricular tachycardia are caused by a reentry phenomenon producing acceler- ated heart rates. Symptoms may include palpitations (including possible pulsations in the neck), chest pain, fatigue, lightheadedness or dizziness, and dyspnea. It is unusual for supraventricular tachycardia to be caused by structurally abnormal hearts. Diagnosis is often delayed because of the misdiagnosis of anxiety or panic disorder. Patient history is important in uncovering the diagnosis, whereas the physical examination may or may not be helpful. A Holter moni- tor or an event recorder is usually needed to capture the arrhythmia and confirm a diagnosis. Treatment consists of short-term or as-needed pharmacotherapy using calcium channel or beta blockers when vagal maneuvers fail to halt or slow the rhythm. In those who require long-term pharmacotherapy, atrioventricular nodal blocking agents or class Ic or III antiarrhythmics can be used; however, these agents should generally be managed by a cardiologist. Catheter ablation is an option in patients with persistent or recurrent supraventricular tachycardia who are unable to tolerate long-term pharmacologic treatment. If Wolff-Parkinson-White syndrome is present, expedient referral
    [Show full text]
  • Cardiac Tamponade Management Clinical Guideline
    Cardiac Tamponade Management Clinical Guideline V1.0 August 2020 Summary Cardiac Tamponade Management Clinical Guideline V1.0 Page 2 of 20 1. Introduction 1.1 Cardiac tamponade is a clinical syndrome caused by the accumulation of fluid, blood, pus, clots or gas in the pericardial space, resulting in reduced ventricular filling and subsequent haemodynamic compromise. This includes a haemodynamic spectrum ranging from incipient or preclinical tamponade (when pericardial pressure equals right atrial pressure but it is lower than left atrial pressure) to haemodynamic shock with significant reduction of stroke volume and blood pressure, the latter representing a life-threatening medical emergency. 1.2 The diagnosis of cardiac tamponade is essentially a clinical diagnosis requiring echocardiographic confirmation of the initial diagnostic suspicion. In most patients, cardiac tamponade should be diagnosed by clinical examination that typically shows elevated systemic venous pressure, tachycardia, muffled heart sounds and paradoxical arterial pulse. Systemic blood pressure may be normal, decreased, or even elevated. Clinical signs may also include decreased electrocardiographic voltage with electrical alternans and an enlarged cardiac silhouette on chest X-ray with slow-accumulating effusions. 1.3 Once a clinical diagnosis of tamponade is suspected, an echocardiogram should be performed without delay. The diagnosis is then confirmed by echocardiographic demonstration of several 2D and Doppler-based findings (i.e. evidence of pericardial effusion with variable cardiac chambers’ compression, abnormal respiratory variation in tricuspid and mitral valve flow velocities, inferior vena cava plethora). 1.4 This should immediately trigger On-call Consultant Cardiologist review in order to stratify the patient risk, identify specific supportive and monitoring requirements and guide the optimal timing and modality of pericardial drainage.
    [Show full text]
  • Rheumatic Mitral Valve Stenosis: Diagnosis and Treatment Options
    Current Cardiology Reports (2019) 21: 14 https://doi.org/10.1007/s11886-019-1099-7 STRUCTURAL HEART DISEASE (RJ SIEGEL AND NC WUNDERLICH, SECTION EDITORS) Rheumatic Mitral Valve Stenosis: Diagnosis and Treatment Options Nina C. Wunderlich1 & Bharat Dalvi2 & Siew Yen Ho3 & Harald Küx1 & Robert J. Siegel4 Published online: 28 February 2019 # Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Purpose of Review This review provides an update on rheumatic mitral stenosis. Acute rheumatic fever (RF), the sequela of group A β-hemolytic streptococcal infection, is the major etiology for mitral stenosis (MS). Recent Findings While the incidence of acute RF in the Western world had substantially declined over the past five decades, this trend is reversing due to immigration from non-industrialized countries where rheumatic heart disease (RHD) is higher. Pre- procedural evaluation for treatment of MS using a multimodality approach with 2D and 3D transthoracic and transesophageal echo, stress echo, cardiac CT scanning, and cardiac MRI as well as hemodynamic assessment by cardiac catheterization is discussed. The current methods of percutaneous mitral balloon commissurotomy (PMBC) and surgery are also discussed. New data on long-term follow-up after PMBC is also presented. Summary For severe rheumatic MS, medical therapy is ineffective and definitive therapy entails PMBC in patients with suitable morphological mitral valve (MV) characteristics, or surgery. As procedural outcomes depend heavily on appropriate case selection, definitive imaging and interpretation are crucial. It is also important to understand the indications as well as morpho- logical MV characteristics to identify the appropriate treatment with PMBC or surgery.
    [Show full text]
  • Cardiac Tamponade And/Or Pericardiocentesis Following Atrial Fibrillation Ablation – National Quality Strategy Domain: Patient Safety
    Quality ID #392 (NQF 2474): HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation – National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Rate of cardiac tamponade and/or pericardiocentesis following atrial fibrillation ablation. This measure is submitted as four rates stratified by age and gender: • Submission Age Criteria 1: Females 18-64 years of age • Submission Age Criteria 2: Males 18-64 years of age • Submission Age Criteria 3: Females 65 years of age and older • Submission Age Criteria 4: Males 65 years of age and older INSTRUCTIONS: This measure is to be submitted a minimum of once per performance period for patients with atrial fibrillation ablation performed during the performance period. This measure may be submitted by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding. NOTE: Include only patients that have had atrial fibrillation ablation performed by November 30, 2018, for evaluation of cardiac tamponade and/or pericardiocentesis occurring within 30 days within the performance period. This will allow the evaluation of cardiac tamponade and/or pericardiocentesis complications within the performance period. A minimum of 30 cases is recommended by the measure owner to ensure a volume of data that accurately reflects provider performance; however, this minimum number is not required for purposes of QPP submission. This measure will be calculated with 5 performance rates: 1) Females 18-64 years of age 2) Males 18-64 years of age 3) Females 65 years of age and older 4) Males 65 years of age and older 5) Overall percentage of patients with cardiac tamponade and/or pericardiocentesis occurring within 30 days Eligible clinicians should continue to submit the measure as specified, with no additional steps needed to account for multiple performance rates.
    [Show full text]
  • Spontaneous Hemopericardium Leading to Cardiac Tamponade in a Patient with Essential Thrombocythemia
    SAGE-Hindawi Access to Research Cardiology Research and Practice Volume 2011, Article ID 247814, 3 pages doi:10.4061/2011/247814 Case Report Spontaneous Hemopericardium Leading to Cardiac Tamponade in a Patient with Essential Thrombocythemia Anand Deshmukh,1, 2 Shanmuga P. Subbiah,3 Sakshi Malhotra,4 Pooja Deshmukh,4 Suman Pasupuleti,1 and Syed Mohiuddin1, 4 1 Department of Cardiovascular Medicine, Creighton University Medical Center, Omaha, NE 68131, USA 2 Creighton Cardiac Center, 3006 Webster Street, Omaha, NE 68131, USA 3 Department of Hematology and Oncology, Creighton University Medical Center, Omaha, NE 68131, USA 4 Department of Internal Medicine, Creighton University Medical Center, Omaha, NE 68131, USA Correspondence should be addressed to Anand Deshmukh, [email protected] Received 30 October 2010; Accepted 29 December 2010 Academic Editor: Syed Wamique Yusuf Copyright © 2011 Anand Deshmukh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Acute cardiac tamponade requires urgent diagnosis and treatment. Spontaneous hemopericardium leading to cardiac tamponade as an initial manifestation of essential thrombocythemia (ET) has never been reported in the literature. We report a case of a 72-year-old Caucasian female who presented with spontaneous hemopericardium and tamponade requiring emergent pericardiocentesis. The patient was subsequently diagnosed to have ET. ET is characterized by elevated platelet counts that can lead to thrombosis but paradoxically it can also lead to a bleeding diathesis. Physicians should be aware of this complication so that timely life-saving measures can be taken if this complication arises.
    [Show full text]
  • Anticoagulant-Induced Hemopericardium with Tamponade: a Case Report and Review of the Literature
    JCEI / Ertaş et al. Hemopericardium with tamponade 2013; 4 (2): 229-233229 Journal of Clinical and Experimental Investigations doi: 10.5799/ahinjs.01.2013.02.0273 CASE REPORT Anticoagulant-induced hemopericardium with tamponade: A case report and review of the literature Antikoagülasyonun indüklediği hemoperikardiyumlu tamponad: Olgu sunumu ve literatür incelemesi Faruk Ertaş, Nihat Polat, Abdulkadir Yıldız, Mustafa Oylumlu, Mehmet Sıddık Ülgen ABSTRACT ÖZET Acute cardiac tamponade requires urgent diagnosis and Akut kardiyak tamponad acil tanı ve tedavi gerektirir. Biz treatment. We report a case of a 43-year-old man who 43 yaşında, erkek ve mitral valv replasmanı sonrası sekiz was receiving warfarin treatment for 8 months following aydır warfarin tedavisi alan bir olguyu aldık. Hastanın bir- mitral valve replacement. The patient had complaint of kaç gündir başlayan nefes darlığı ve halsizlik şikayetikleri dyspnea and fatigue for a few days. Cardiac tamponade mevcuttu. Kardiyak tamponad tanısı konuldu ve 1400 ml was diagnosed, and the INR at that time was 10.4. Urgent mai perikardiyosentezle acil olarak drene edildi. Tanı sı- pericardiocentesis were undertaken and 1400 ml of peri- rasında İNR değeri çok yüksek olan hastaya Vitamin K cardial blood was drained. Following surgery the patient’s antagonistleri ve taze donmuş plazma verilerek yuksek recovery was uneventful. An intravenous vitamin K injec- koagülasyon durumu geriye döndürüldü. Patolojik incele- tion and fresh frozen plasma transfusion were adminis- me sonucunda enfeksiyon ve malingnensi saptanmadı. tered to reverse the patient’s over-anticoagulated state. Hastada kronik inflamasyon düşünüldü. Sonuç olarak The final pathology revealed chronic inflammation and warfarin overdoz acil bir durum olup hemoperikardiyumla there was no malignancy, and no bacteria or mycobacte- tamponada yol açabilmektedir.
    [Show full text]